Tesamorelin (20mg Vial) Dosage Protocol

Overview

Tesamorelin is a synthetic 44-amino-acid peptide that mimics Growth Hormone-Releasing Hormone (GHRH). It stimulates the body’s natural growth hormone release and elevates IGF-1 levels, promoting fat breakdown and metabolic improvements. The FDA approved this compound for reducing visceral adipose tissue in HIV-associated lipodystrophy, though researchers also investigate its potential for metabolic disorders and aging-related concerns.

Quick Reference

– Reconstitution: Mix 3.0 mL bacteriostatic water per 20 mg vial, yielding approximately 6.67 mg/mL
– Standard Dose: 2 mg (2000 mcg) once daily via subcutaneous injection after initial titration
– Duration: 12–26 weeks typical; some studies extend to 52 weeks with medical oversight
– Storage: Refrigerate lyophilized vials at 2–8°C; refrigerate reconstituted solutions at the same temperature
– Timing: Evening administration aligns with natural growth hormone release patterns

Dosing Schedule

The first week at a reduced dose allows the body to adapt before advancing to the full therapeutic amount.

Mechanism of Action

Tesamorelin binds to pituitary GHRH receptors, triggering pulsatile growth hormone secretion. This cascade raises IGF-1 levels, which promotes lipolysis (fat cell breakdown), muscle protein synthesis, and metabolic rebalancing. Clinical evidence shows significant visceral fat reduction after 3–6 months of consistent daily use, with measurable improvements in lipid profiles in many patients.

Supplies Required

For an 8-week protocol:
– 6 vials of Tesamorelin (20 mg each)
– 56 insulin syringes (U-100, 1 mL capacity)
– 18 mL bacteriostatic water (two 10 mL bottles)
– 112 alcohol swabs

For a 12-week protocol:
– 9 vials
– 84 syringes
– 27 mL bacteriostatic water (three 10 mL bottles)
– 168 alcohol swabs

For a 16-week protocol:
– 11 vials
– 112 syringes
– 33 mL bacteriostatic water (four 10 mL bottles)
– 224 alcohol swabs

Reconstitution Steps

1. Draw 3.0 mL of bacteriostatic water using a sterile syringe
2. Inject slowly down the interior vial wall to minimize foam formation
3. Gently swirl the vial until the powder dissolves completely
4. Avoid vigorous shaking
5. Label with the reconstitution date and time
6. Store at 2–8°C, protected from direct light

Once reconstituted with bacteriostatic water, the solution remains stable for approximately 14 days under proper refrigeration.

Injection Technique

– Clean the vial stopper and injection site thoroughly with alcohol swabs; allow both to air-dry completely
– Pinch a skinfold at the injection site (preferably the abdomen, at least 2 inches from the navel)
– Insert the needle at a 90° angle if adequate subcutaneous fat is present, or 45° if tissue is lean
– Release the pinch before injecting
– Administer the injection slowly; wait 2–3 seconds before withdrawing the needle
– Rotate injection sites systematically among the abdomen, thighs, and upper arms to prevent tissue damage
– Dispose of used syringes immediately in a sharps container

Storage & Stability

Lyophilized (Unreconstituted):
Standard formulations: store at 2–8°C
Newer formulations (Egrifta SV): may remain stable at room temperature (20–25°C) before reconstitution

Reconstituted with Bacteriostatic Water:
Refrigerate at 2–8°C for up to 14 days

Reconstituted with Sterile Water:
Use immediately; discard any unused portion

Important: Never freeze reconstituted solutions; repeated freeze-thaw cycles degrade the peptide.

Potential Benefits

– Significant reduction in visceral fat deposits (measurable after 3–6 months)
– Improved lipid panel results
– Potential liver fat reduction in patients with non-alcoholic fatty liver disease
– Enhanced cognitive function (ongoing research in older adults)
– Well-tolerated with sustained benefits through 52 weeks of continuous use

Common Side Effects

Local reactions:
– Mild redness, itching, pain, or bruising at injection sites

Systemic effects:
– Joint pain and muscle aches
– Mild swelling in extremities (peripheral edema)
– Occasional tingling or numbness in hands/fingers (carpal tunnel-like symptoms, typically dose-dependent and reversible)

Metabolic considerations:
– IGF-1 elevation requires periodic monitoring
– Small increases in blood glucose markers observed in some patients
– Blood glucose monitoring recommended for diabetic individuals

Contraindications

– Active malignancies (tesamorelin may promote tumor growth)
– Pregnancy (potential fetal harm)
– Known hypersensitivity to the compound or mannitol excipient

Important Monitoring Notes

– Track IGF-1 levels periodically due to potent growth hormone stimulation
– Monitor blood glucose in individuals with diabetes or prediabetes
– Document daily doses and injection site rotation for consistency
– Rotate sites systematically to avoid lipohypertrophy (abnormal fat accumulation)
– Observe for any signs of carpal tunnel syndrome; dose adjustment may be necessary

Lifestyle Integration

Diet: Maintain a balanced, protein-rich diet to support the anabolic effects of elevated GH/IGF-1

Exercise: Combine with resistance training and aerobic activity to maximize fat loss and metabolic improvements

Sleep: Prioritize 7–9 hours of quality sleep nightly to optimize natural GH pulsatility

Stress Management: Practice mindfulness or relaxation techniques to support adherence and recovery

Important Disclaimer

This protocol is provided for educational and research purposes only. Tesamorelin is a prescription medication (FDA-approved as Egrifta®) for HIV-related lipodystrophy. Any use outside this approved indication requires compliance with applicable laws and medical supervision. Consult a qualified healthcare professional before initiating any therapeutic regimen involving tesamorelin.